Shattuck Labs, Inc. Common Stock STTK
Analyst Ratings
- Consensus
- Buy — 10 Buy · 0 Hold · 0 Sell (10 analysts)
- Avg. Price Target
- $15.67 (+193.9% upside)
Key Stats
- Today's Range
- $5.19 – $5.52
- 50-Day Range
- $5.19 – $8.15
- 52-Week Range
- $1.68 – $8.33
- Volume
- 1.20 million shs
- Average Volume
- 1.44 million shs
- Market Cap
- $550.99 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.64%
- Days to Cover
- 1.29
About Shattuck Labs, Inc. Common Stock
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Related Stocks
Compare head-to-head: STTK vs LLY·STTK vs JNJ·STTK vs ABBV·STTK vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
